Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
ADC ID |
DRG0MMQHZ
|
|||||
---|---|---|---|---|---|---|
ADC Name |
SNS-622-DM1
|
|||||
Synonyms |
SNS-622 DM1
Click to Show/Hide
|
|||||
Drug Status |
Investigative
|
|||||
Indication |
In total 1 Indication(s)
Pancreatic ductal adenocarcinoma [ICD11:2C10]
Investigative
|
|||||
Drug-to-Antibody Ratio |
5.08
|
|||||
Antibody Name |
SNS-622
|
Antibody Info | ||||
Antigen Name |
Aspartyl/asparaginyl beta-hydroxylase (ASPH)
|
Antigen Info | ||||
Payload Name |
Mertansine DM1
|
Payload Info | ||||
Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
Linker Name |
Maleimido-caproyl
|
Linker Info | ||||
Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
General Information of The Activity Data Related to This ADC
Discovered Using Patient-derived Xenograft Model
Standard Type | Value | Units | Animal Model (No. of PDX) |
---|---|---|---|
Tumor Growth Inhibition value (TGI) |
≈ 36.75
|
%
|
Pancreatic ductal adenocarcinoma PDX model
|
Discovered Using Cell Line-derived Xenograft Model
Standard Type | Value | Units | Cell Line | Disease Model |
---|---|---|---|---|
Tumor Growth Inhibition value (TGI) |
≈ 55.56
|
%
|
MIA PaCa-2 cells
|
Pancreatic ductal adenocarcinoma
|
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Patient-derived Xenograft Model
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 36.75% (Day 56) | Positive ASPH expression (ASPH +++/++) | ||
Method Description |
Mice bearing an approximately 100 mm3 tumor xenograft were intravenously injected weekly with 2.5 mg/kg of SNS-622 or SNS-622-DM1, and tumor growth was monitored.
|
||||
In Vivo Model | Pancreatic ductal adenocarcinoma PDX model |
Discovered Using Cell Line-derived Xenograft Model
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 55.56% (Day 22) | Positive ASPH expression (ASPH +++/++) | ||
Method Description |
MIA PaCa2-empty vector and MIA-PaCa2-ASPH cell lines generated sc tumors in the NSG mice were treated with SNS-622-DM1 (5 mg/kg. every 7 day) and a non-relevant IgG mAb also conjugated with DM1.
|
||||
In Vivo Model | MIA PaCa2 CDX model | ||||
In Vitro Model | Pancreatic ductal adenocarcinoma | MIA PaCa-2 cells | CVCL_0428 |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.